• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » FDA clears Nexpowder endoscopic hemostasis system from Medtronic

FDA clears Nexpowder endoscopic hemostasis system from Medtronic

September 29, 2022 By Sean Whooley

Medtronic Nexpowder
The Nexpowder system. [Image from Medtronic]
Medtronic (NYSE:MDT) announced that it received FDA clearance for its Nexpowder endoscopic hemostasis system.

Nexpowder uses a noncontact, nonthermal and nontraumatic hemostatic powder. The powder sprays through a catheter that features a proprietary powder-coating technology for minimized clogging.

The Nexpowder design provides improved visibility and control in the treatment of upper gastrointestinal (GI) nonvariceal bleeding. According to a news release, upper GI bleeding accounts for 75% of all acute GI bleeding cases.

“We are very excited to bring the innovative, Nexpowder system to gastroenterologists. We considered the potential impact on physicians and patients alike, by meeting a clear need to reduce mortality from upper GI bleeding, a condition that causes death for one out of every 1,000 people while also reducing rebleeding, which happens in 20% of all upper GI bleeding cases,” said Gio Di Napoli, president of the Gastrointestinal business at Medtronic. “The Medtronic GI business is striving – across all products in our portfolio – to create transformative technologies that improve outcomes and change the standard of care.” 

How it works

Nexpowder is sprayed onto a target site endoscopically through the catheter, which connects to a spray handle. Once sprayed it forms a mucoadhesive and durable gel upon contact, with or without blood. The gel then degrades in one-to-three days.

The spray adheres to the tissue with double the adhesive force of other commercially available products, Medtronic said. This results in a durable hemostatic effect. Altogether, the company said Nexpowder provides a solution for nonvariceal upper GI bleeding with minimal scattering or clogging, enabling direct endoscopic visibility without impairment.  

Nexpowder also doesn’t require CO2 or air compressors. Its proprietary hydrophilic polymer enables controlled delivery to minimize clogging and maintain endoscopic visibility.

“With a 94% immediate hemostasis rate and a 3.7% rebleeding rate, we’re thrilled to share this effective technology with gastroenterologists,” said Dr. Austin Chiang, CMO of the Gastrointestinal business at Medtronic. “When we treat patients, we’re looking for immediate and lasting results when it matters most. The Nexpowder system is a powerful tool for GI professionals to add to their toolboxes.” 

Filed Under: 510(k), Blood Management, Business/Financial News, Endoscopic, Featured, News Well, Regulatory/Compliance Tagged With: FDA, Medtronic

More recent news

  • Massachusetts Life Sciences Center offers grants to lower medtech commercial risk
  • The 10 largest medical device companies
  • CSL to drop Terumo for Haemonetics in US plasma collection supply deal
  • How 5 medtech CEOs design for access
  • Butterfly Network to chase ultrasound brain-computer interfaces with newcomer Bridge Neurotech

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy